Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of the 30 mg Intravenous Formulation of the Neurokinin-1 Receptor Antagonist GW679769 for Prevention of Postoperative Nausea and Vomiting in Female Subjects at High Risk for Emesis

NCT00334152 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00334152
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00334152 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of the 30 mg Intravenous Formulation of the Neurokinin-1 Receptor Antagonist GW679769 for Prevention of Postoperative Nausea and Vomiting in Female Subjects at High Risk for Emesis
Lead sponsor
GlaxoSmithKline
Phase
Phase 3
Overall status
Completed
Start date
March 31, 2006
Completion date
July 31, 2006
Enrollment
515 (actual)
Sites
70

Conditions

As the registry lists them; a condition with its own page is linked.

nausea and vomiting, postoperative, postoperative nausea and vomiting